补肾化瘀法治疗良性前列腺增生症的临床研究

目的 观察补肾化瘀汤治疗前列腺增生症（BPH）患者的临床疗效.方法 采用随机对照法将80例患者分为治疗组（补肾化瘀汤）和对照组（西药：舍尼通）,各40例.行3个疗程（3个月）的治疗.记录国际前列腺症状评分（IPSS）、最大尿流率、前列腺体积、血清胰岛素样生长因子1（IGF-1）的变化,统计分析两组病例治疗前后变化.结果 治疗组的IPSS为（8.35±5.56）,最大尿流率为（14.52±3.56） ml/s,前列腺体积为（32.52±7.56） cm3,IGF-1为（268.31±16.35）μg/L,均较治疗前有显著性差异,差异具有统计学意义（P＜0.05）,而治疗组的IPSS、最大尿流率,前列腺体积,IGF-1与对照组比较,差异具有统计学意义（P＜0.05）.结论 补肾化瘀汤能够有效地改善前列腺增生症临床症状.     

A Pollen Extract (Cernilton) in Patients with Inflammatory Chronic Prostatitis–Chronic Pelvic Pain Syndrome: A Multicentre, Randomised, Prospective, Double-Blind, Placebo-Controlled Phase 3 Study

Background

National Institutes of Health (NIH) category III prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent condition for which no standardised treatment exists.

Objectives

To assess the safety and efficacy of a standardised pollen extract in men with inflammatory CP/CPPS.

Design, setting, and participants

We conducted a multicentre, prospective, randomised, double-blind, placebo-controlled phase 3 study comparing the pollen extract (Cernilton) to placebo in men with CP/CPPS (NIH IIIA) attending urologic centres.

Intervention

Participants were randomised to receive oral capsules of the pollen extract (two capsules q8 h) or placebo for 12 wk.

Measurements

The primary endpoint of the study was symptomatic improvement in the pain domain of the NIH Chronic Prostatitis Symptom Index (NIH-CPSI). Participants were evaluated using the NIH-CPSI individual domains and total score, the number of leukocytes in post–prostatic massage urine (VB3), the International Prostate Symptom Score (IPSS), and the sexuality domain of a life satisfaction questionnaire at baseline and after 6 and 12 wk.

Results and limitations

In the intention-to-treat analysis, 139 men were randomly allocated to the pollen extract (n = 70) or placebo (n = 69). The individual domains pain (p = 0.0086) and quality of life (QoL; p = 0.0250) as well as the total NIH-CPSI score (p = 0.0126) were significantly improved after 12 wk of treatment with pollen extract compared to placebo. Response, defined as a decrease of the NIH-CPSI total score by at least 25% or at least 6 points, was seen in the pollen extract versus placebo group in 70.6% and 50.0% (p = 0.0141), respectively. Adverse events were minor in all patients studied.

Conclusions

Compared to placebo, the pollen extract significantly improved total symptoms, pain, and QoL in patients with inflammatory CP/CPPS without severe side-effects.     

舍尼通、左旋氧氟沙星联合超短波治疗慢性前列腺炎的效果

目的:探讨舍尼通、左旋氧氟沙星与超短波联合治疗慢性前列腺炎的效果。方法:60例慢性前列腺炎患者采用舍尼通、左旋氧氟沙星口服,同时联合超短波电疗,治疗疗程为4周。结果:总有效率达82%,治愈率为37%;而且主、客观的临床指标均有显著性改善,无其他不良反应。结论:舍尼通、左旋氧氟沙星联合超短波是一种有效的治疗慢性前列腺炎的方法。     

Dietary supplements for benign prostatic hyperplasia: An overview of systematic reviews

Benign prostatic hyperplasia (BPH) is a common chronic condition in older men. The aim of this overview of systematic reviews (SRs) is to summarise the current evidence on the efficacy and adverse effects of dietary supplements for treating BPH with lower urinary tract symptoms. We searched 5 electronic databases and relevant overviews without limitations on language or publication status. Six SRs of 195 articles were included in this overview. Serenoa repens was reviewed in 3 studies and no specific effect on BPH symptoms and urinary flow measures was observed. However, β-sitosterol, Pygeum africannum and Cernilton were reviewed in one study each, and significant improvement was observed for all three. All the included compounds have mild and infrequent adverse effects. SRs on β-sitosterol, Pygeum africannum and Cernilton have not been updated since 2000, thus an update of reviews on these compounds will be necessary in the future.     

Identification of a prostate inhibitory substance in a pollen extract

Recently, much attention has focused on the treatment of BPH with the pollen extract, Cernilton. The present investigation was designed to identify the active component in this agent which might be responsible for the symptomatic relief of BPH as previously reported [1,2]. Sequential purification of the active component present in the pollen extract was carried out by a combination of dialysis, gel filtration, and reverse phase chromatography. To monitor the biological activity of each of the purified fractions, a biological assay employing the human prostate cancer cell line DU145 was undertaken. While we have identified a number of constituent components in the pollen extract, only one fraction designated V-7 (FV-7) maintained a strong inhibitory effect on the growth of DU145 cells. The inhibition was time- and dose-dependent, and the concentrations of FV-7 required to reduce the cell numbers by 50% (IC₅₀) after 2 days of exposure was 5 μg/ml. FV-7 was also inhibitory towards the primary culture of prostate stroma and epithelial cells, with the stroma/fibroblast showing greater sensitivity towards the HPLC-purified component. However, it should be noted that this inhibitory activity measured in the primary culture cells was only achieved at higher concentrations of FV-7. Preliminary characterization of the active ingredient identified FV-7 as DIBOA which is a cyclic hydroxamic acid. FV-7 and DIBOA induce similar inhibitory effects on the growth of DU145 cells.     

补肾化瘀汤治疗良性前列腺增生症40例临床观察

目的：观察补肾化瘀汤治疗前列腺增生症（BPH）的临床疗效。方法：将80例本病患者随机分为治疗组和对照组各40例。治疗组予补肾化瘀汤治疗,对照组予舍尼通片治疗。两组均以1个月为一个疗程,治疗3个疗程。观察两组患者国际前列腺症状评分（IPSS）、最大尿流率、前列腺体积、血清胰岛素样生长因子-1（IGF-1）的变化。结果：总显效率治疗组为86.5%,对照组为55.1%,治疗组优于对照组,差异有统计学意义（P〈0.05）。两组的IPSS、最大尿流率、前列腺体积、IGF-1均较治疗前改善,差异有统计学意义（P〈0.05）,而治疗组的IPSS、最大尿流率、前列腺体积、IGF-1改善情况优于对照组,差异有统计学意义（P〈0.05）。结论：补肾化瘀汤治疗良性前列腺增生症有较好疗效,可有效地改善前列腺增生症临床症状。     

大剂量舍尼通治疗轻中度良性前列腺增生尿动力学评价

目的 利用尿动力学检查评价大剂量舍尼通治疗轻中度良性前列腺增生的疗效.方法 80例轻中度良性前列腺增生患者[7分＜国际前列腺症状评分(IPSS)≤20分]口服舍尼通1年,每次750mg,每日3次;在治疗前、治疗后3、6及12个月通过IPSS、最大尿流率(Qmax)测定、残余尿量(PVR)测定、压力-流率(A-G)检查评价疗效.结果 80例患者随访(1.2±1.6)年,其中26例退出试验,54例患者治疗前IPSS为(20.5±4.5)分,PVR为(42.5±8.2)ml,Qmax为(10.2±2.3)ml/s,A-G值为56.5±12.8、最大尿流率时逼尿肌压力(PQmax1)为(54.8±13.7)mmHg(1mmHg=0.133kPa).治疗后12个月IPSS为(11.0±3.3)分,PVR为(15.9±7.4)ml,Qmax为(15.7±2.5)ml/s,A-G值为49.2±13.6,PQmax为(43.6±14.9)mmHg.治疗后12个月较治疗前Qmax有明显提高(P＜0.05),PVR、IPSS、A-G值、PQmax明显下降(P＜0.05).结论 大剂量舍尼通治疗良性前列腺增生疗效满意,治疗后各项尿动力学检查参数明显改善.     

舍尼通改善3型前列腺炎患者精液质量的研究

目的:研究舍尼通能否改善3型前列腺炎患者的精液质量。方法:将门诊62名3型前列腺炎患者分为空白对照组与舍尼通组进行研究,分析精液液化时间、精子活力、精子活率。结果:舍尼通能够改善3型前列腺炎患者的精液质量,发挥疗效。结论:舍尼通可能是通过调节氧化应激反应而发挥3型前列腺炎患者的生精调节,未来可能有助于治疗男性不育症。     

植物制剂普适泰对女性顽固下尿路刺激征的疗效观察

目的了解普适泰（舍尼通）对女性下尿路病变患者顽固存在的排尿刺激症状的疗效。方法将60例经抗炎或手术治疗后仍有不同程度排尿刺激症状存在的女性下尿路病变患者随机分为：①A组（30例）：患者接受普适泰片口服治疗；②B组（30例）：患者仅予安慰剂口服作对照组。通过国际下尿路症状（Lower urinary tract symptoms，LUTS）评分和生活质量（Quality of life，QOL）评分变化，比较分析两组疗效。结果治疗4周后，A组LU偈和QOL评分变化均优于B组，差异有统计学意义（P〈0．05）。结论口服普适泰片有助于改善女性患者顽固的下尿路刺激征状。     

舍尼通治疗慢性非细菌性前列腺炎和前列腺痛的临床研究(附40例报告)

为探讨舍尼通治疗慢性非细菌性前列腺炎和前列腺癌的效果。我院自1997年7月～1997年11月应用舍厄通治疗40例慢性非细菌前列腺炎和前列腺痛,治疗疗程为4周。总有效率为72.5％,治愈率为32.5％,而且主、客观的临床指标均有显著性改善,并且无其它副作用。本临床研究结果表明舍尼通可作为治疗慢性前列腺炎的药物。